Clinical boundarySchedule I in the U.S.Serious cardiac riskNot FDA-approvedNo dosing or referralsSchedule I · cardiac riskNot FDA-approved · no referrals
Safety
Safety desk
LAST REVIEWED 2026-06-30 · 815 SOURCES · 0 CORRECTIONS
Safety is the first clinical topic, not the last paragraph. Ibogaine coverage has to foreground QT/QTc, rhythm risk, medication interactions, exclusions, adverse events, and emergency readiness before benefit language.
Review status: Source-compiled educational explainer; pending named medical review. This page does not provide dosing, self-screening instructions, treatment protocols, provider referrals, or emergency guidance.
Ibogaine is associated with serious cardiac and interaction risks. Research settings and medical discussions emphasize medical screening, monitoring, exclusion criteria, medication review, and emergency response capacity. IbogaBase covers those topics so readers understand the risk conversation; it does not tell anyone how to self-assess or use Ibogaine.
QT/QTc and rhythm
The QT interval is an ECG measurement; QTc is corrected for heart rate. Published reviews and case reports repeatedly discuss QT/QTc prolongation, bradycardia, ventricular arrhythmia, cardiac arrest, and death. The denominator is incomplete because many uses occur outside standardized research settings.
CYP2D6, metabolism, and interactions
Human pharmacokinetic work describes meaningful person-to-person variability, including CYP2D6-related metabolism. Medication review matters because QT-prolonging, serotonergic, stimulant, sedative, opioid, psychiatric, and metabolism-affecting drugs can change the risk conversation.
Electrolytes, exclusions, and adverse events
Electrolyte abnormalities, cardiac history, psychiatric instability, polysubstance exposure, withdrawal contexts, and other exclusion concerns appear in safety discussions. Adverse event records are tracked with caution because causality and event rates can be hard to interpret from incomplete reports.
Emergency readiness
Reputable research and medical discussions treat emergency readiness as part of safety, not an afterthought. IbogaBase documents that standard without publishing operational protocols.
Why fatality rates cannot be calculated
Reports count deaths temporally associated with ibogaine, but there is no reliable denominator: no one knows the total number of ibogaine exposures worldwide, because most use happens outside clinics, registries, or research settings. Without a trustworthy total-exposure figure, a population fatality rate cannot be calculated. Statements like "the death rate is one in X" are not supportable from the current record. The honest framing is that serious cardiac events and deaths are documented, that their true frequency per exposure is unknown, and that the settings of reported deaths matter more than any single rate.
What a monitored study measured (Knuijver et al., 2022)
A Dutch monitored inpatient study by Knuijver and colleagues (Addiction, 2022) followed a small group of opioid-dependent participants receiving a single supervised ibogaine session with continuous ECG. The maximum QTc prolongation averaged roughly 95 milliseconds, about half of participants reached a QTc above 500 milliseconds during monitoring, and prolongation above 450 milliseconds persisted beyond 24 hours in several participants. No torsades de pointes occurred under monitoring. This is a small observational safety study, attributed to its authors; it documents the size and duration of the QTc effect, not a safe way to take ibogaine.
What the fatality literature shows (Alper and colleagues)
A review of fatalities temporally associated with ibogaine (Alper, Stajić, and Gill, Journal of Forensic Science, 2012) found that reported deaths clustered in specific settings: unsupervised or non-clinical administration, polysubstance exposure, pre-existing cardiovascular disease, and the absence of cardiac telemetry or emergency readiness. Case reports and case series can establish that serious harm has occurred and describe its context; they cannot by themselves establish causality, per-exposure risk, or a fatality rate.
Ibogaine metabolism to noribogaine involves the enzyme CYP2D6, which varies widely between people. CYP2D6 poor metabolizers, and people taking CYP2D6-inhibiting medications, can have very different ibogaine exposure and clearance, which is one reason the same amount does not carry the same risk for everyone. Combining ibogaine with other QT-prolonging drugs or with CYP2D6 inhibitors is repeatedly flagged as raising cardiac risk. This is a description of pharmacology, not screening or dosing guidance.
What published screening protocols exclude
This list describes, in general terms, the kinds of people whom published ibogaine screening protocols and clinical guidelines commonly exclude. It is descriptive of the literature, not a self-assessment tool, clearance checklist, or instruction to proceed.
People with known QT/QTc prolongation, significant cardiac history, structural heart disease, or serious arrhythmia risk.
People with uncorrected electrolyte abnormalities, including low potassium or magnesium.
People taking QT-prolonging medications, CYP2D6 inhibitors, or certain serotonergic, stimulant, or interacting drugs.
People with active psychiatric instability, including psychosis, mania, or acute suicidality.
People who are pregnant, or who have significant liver, kidney, or other organ compromise.
Source basis: published literature-screening-protocol and clinical-guideline descriptions, including the Global Ibogaine Therapy Alliance clinical guidelines. Screening decisions belong to qualified clinicians, not to a public reference page.
Guideline and safety-education sources
Source-labeled bodies whose ibogaine safety and clinical-guideline material is widely cited. Described as source material, not IbogaBase-endorsed protocol.
OrganizationConfidence: Moderate
Guidelines and education
Global Ibogaine Therapy Alliance (GITA)
GITA is a widely cited source of ibogaine safety and clinical-guideline material that a safety-first reference should track.
The Global Ibogaine Therapy Alliance (GITA) published Clinical Guidelines for Ibogaine-Assisted Treatment, a frequently cited document in ibogaine safety discussion.
Those clinical guidelines emphasize cardiac screening, medical monitoring, exclusion criteria, and emergency readiness.
IbogaBase describes GITA guidelines as source material, not as an IbogaBase-endorsed or IbogaBase-published protocol.
Related searches: GITA · Global Ibogaine Therapy Alliance · clinical guidelines
What this does not prove: Published guidelines are source material describing risk-management practice; they are not IbogaBase endorsement, not proof of efficacy, and not a protocol to follow.